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Laboratory quality is continuously present in our daily practice of molecular diagnosis in human 
genetics. Our participation in external quality assessment (EQA), specially with EMQN, gave us the 
opportunity to improve the reports of our genetic tests, to compare our performance/scores with other 
European laboratories, and to be permanently updated with the most recent recommendations for 
best practice in human molecular diagnosis.  
Since 2005, our lab has been participating in the EMQN external quality assessment program for the 
molecular diagnosis of hereditary haemochromatosis HFE-associated (HH-HFE). Since then, our 
score regarding the genotyping category has achieved every year the highest marks (2.0), while for 
the interpretation category, in two years, the mean score was 1.75.  These scores lead us to improve 
the “interpretation section” of our reports in order to give the best result to the physicians and 
patients. In addition of a correct genotyping, the report “interpretation section” is particularly 
important, it should include the main suggestions for the best patient’s clinical management: i) 
immediate impact of the result for the patient, ii) patient’s clinical follow-up and other diagnostic 
options, iii) long term-impact (specially in predictive tests), iv) relevance of the result for relatives 
and, v) recommendations of genetic counselling.  
In accordance with OCDE disease specific guidelines for quality assurance in molecular genetic 
testing, and with the requirements of ISO 15189, in 2014 we were the first Portuguese laboratory 
accredited by IPAC, for HH-HFE - variants p.H63D and p.C282Y, and other genetic tests 
(http://www.ipac.pt/pesquisa/ ficha_15189.asp?id=E0015). Accreditation under the International 
Standard ISO 15189 is challenging but contributes to introduce improvements in our current practice 
because it comprises “management requirements” (e.g. quality management system, external 
services and supplies, preventive and corrective actions, control of records) and “technical 
requirements” (e.g. accommodation and environmental conditions, laboratory equipment, reagents 
and consumables, training and qualifications of personnel, examination processes, results reporting).   
Accreditation enhances laboratory quality at different levels, gives credibility, competency and 
confidence, but primarily contributes to a better patient’s clinical diagnosis reducing the turnaround 
time, patient management and treatment, and genetic counselling. 
 
